Jean-francois Gestin

Nantes, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

211At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

211At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 24, 2026

"Tumor Targeting, Imaging, RadiotherapieS" 17th edition of the workshop organized by the Cancéropôle Grand-Ouest, October 9-12, 2024, Erquy, France

"Tumor Targeting, Imaging, RadiotherapieS" 17th edition of the workshop organized by the Cancéropôle Grand-Ouest, October 9-12, 2024, Erquy, France

Journal: Bulletin du cancer
Published: December 10, 2025

Bambusuril as an effective astatide sequestrating agent by hydrogen bonding.

Bambusuril as an effective astatide sequestrating agent by hydrogen bonding.

Journal: Chemical communications (Cambridge, England)
Published: July 17, 2025

Preparation of 211At-Labeled (Hetero)aryl Compounds from Triarylsulfonium and Dibenzothiophenium Salts.

Preparation of 211At-Labeled (Hetero)aryl Compounds from Triarylsulfonium and Dibenzothiophenium Salts.

Journal: Organic letters
Published: June 18, 2025

Corrigendum to "Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy" [Nucl Med Biol (March-April 2025) 108990].

Corrigendum to "Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy" [Nucl Med Biol (March-April 2025) 108990].

Journal: Nuclear medicine and biology
Published: March 18, 2025

Formation Of Gold-Astatine Bonds in N-Heterocyclic Carbene Complexes.

Formation Of Gold-Astatine Bonds in N-Heterocyclic Carbene Complexes.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: March 02, 2025

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.

Journal: Cancers
Published: February 10, 2025

Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.

Journal: Nuclear medicine and biology
Published: November 09, 2024

Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.

Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.

Journal: EJNMMI radiopharmacy and chemistry
Published: August 02, 2024

Sydnone-based prosthetic groups for radioiodination.

Sydnone-based prosthetic groups for radioiodination.

Journal: Bioorganic & medicinal chemistry
Published: June 25, 2024

"Adaptation of the tumour and its ecosystem to radiotherapies: Mechanisms, imaging and therapeutic approaches" XIVth edition of the workshop organised by the "Vectorisation, Imagerie, Radiothérapies" network of the Cancéropôle Grand-Ouest, 22-25 September 2021, Le Bono, France

"Adaptation of the tumour and its ecosystem to radiotherapies: Mechanisms, imaging and therapeutic approaches" XIVth edition of the workshop organised by the "Vectorisation, Imagerie, Radiothérapies" network of the Cancéropôle Grand-Ouest, 22-25 September 2021, Le Bono, France

Journal: Bulletin du cancer
Published: March 21, 2022

211 At and 125 I-Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again.

211 At and 125 I-Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: November 19, 2021
Showing 1-12 of 27

Last Updated: 09/26/2026